Who We Are

A Patient-centered Health Intelligence Company Advancing Healthcare Through Data-driven Insights

Sema4 is transforming healthcare by using artificial intelligence to enable the delivery of precision medicine as the standard of care.

Who We Are

A Patient-centered Health Intelligence Company Advancing Healthcare Through Data-driven Insights

Sema4 is transforming healthcare by using artificial intelligence to enable the delivery of precision medicine as the standard of care.

Centrellis®:
Our Health Data Engine

Our unique analytics platform, Centrellis, enables us to transform standard of care insights by reconstructing longitudinal patient journeys, derive population health insights, and deliver AI-powered disease models.
 

Robust
Research

Sema4’s accomplished research team includes world leaders in data science, machine learning, network modeling, and genomics. We’ve published more than 180 peer-reviewed papers and are committed to providing science-driven solutions to the most pressing medical needs.

Our areas of focus

Women’s Health

Our Sema4 Elements portfolio of information-driven genomic solutions, digital tools, and services enables providers to treat patients holistically during their reproductive and generational health journey, from preconception planning to hereditary cancer testing.

Precision Oncology

Our family of precision oncology products and services, Sema4 Signal®, provides data-driven care solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.

Biopharma

Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.

Latest News

January 18th, 2022

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Sema4 has signed a definitive agreement to acquire GeneDx, a leader in genomic testing and analysis, positioning Sema4 to further transform the standard of care.
January 10th, 2022

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021

Sema4’s fourth quarter and fiscal year results are expected to exceed the high end of guidance for both total revenue and resulted test volume.
November 15th, 2021

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights

Sema4 reported the financial results for the third quarter ended September 30, 2021 and provided an update on key strategic and operational initiatives.
Featured In
CBS logoBloomberg logo
Awards & Recognition
Forbes
List of America’s Best Startup Employers
Gartner
Cool Vendor in Healthcare Technology
CB Insights
Digital Health 150
U.S. Senator
Chris Murphy’s
Innovator of the Month